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CASE 1 
 
Deciding Value for Money: 
Improving Prenatal Genetic Screening in Ontario 
 
 
Dawn Beck, RN, MPH (MPH Class of 2014) 
Julie Toole, RM, MHSc (Risk Management Specialist, Association of Ontario Midwives) 
Ava John-Baptiste, PhD (Assistant Professor, Western University) 
 
 
BACKGROUND 
The Ministry of Health and Long-Term Care (MOHLTC) has supported prenatal genetic 
screening in Ontario since 1993, publically funding an array of screening options. In February 
2013, a new screening option became available in Ontario. This technology, known as non-
invasive prenatal testing (NIPT), promises improved accuracy and safety and is currently only 
available to those willing to independently pay for the test (Okun, Teitelbaum, Huang, Dewa, & 
Hoch, 2014). With increasing public interest in the technology and wanting to maintain a 
centralized, standardized, high quality provincial screening program, the Ministry has 
recognized the need for an urgent response on the use of NIPT within the public system. In 
March 2014, the Ministry appointed a Prenatal Genetic Screening Group (PGSG) to advise on 
current screening practices and make recommendations for an improved prenatal genetic 
screening program in Ontario. As part of the group’s work, the Ministry has requested an 
economic evaluation, examining the costs and performance outcomes associated with NIPT 
and its introduction into the public system.  
 
INTRODUCTION TO PRENATAL GENETIC SCREENING 
Prenatal genetic screening for fetal chromosomal abnormalities began in the mid-1960s. At this 
time the screening involved offering women who were considered of advanced maternal age 
(>35 years of age at expected date of delivery) an invasive test called an amniocentesis. This 
test carried with it a small risk of fetal loss (0.01% to 0.5%). The age 35 was chosen as it was 
the determined point where the risk of fetal loss related to screening was less than the chance 
of identifying a significant fetal chromosomal condition (Prenatal Screening Ontario, 2014). 
Since this time, great advances in prenatal genetic technology have been made, lessening the 
need for invasive testing and subsequently reducing the number of fetal losses due to 
complications. Today, prenatal genetic screening consists of minimally invasive procedures 
such as blood work and ultrasounds and has become a routine part of publicly funded prenatal 
care for all women in Ontario. 
 
Women may choose to have screening done if they wish to learn more about their pregnancy, 
want to gather the best information and prepare for their newborn and the delivery, or want the 
opportunity to terminate a pregnancy if a diagnosis is made. Prenatal genetic screening does 
not screen for all chromosomal abnormalities nor does it provide a definitive diagnosis. Women 
who receive a positive screen are given the option of further diagnostic testing. This consists of 
either chorionic villus sampling (CVS) or amniocentesis. Both procedures carry a small risk of 
fetal loss (1% and 0.01% to 0.5% respectively; Prenatal Screening Ontario, 2014). 
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With the discovery of cell-free fetal DNA (cffDNA) in maternal blood, a new form of screening 
has evolved. This screening is referred to as non-invasive prenatal testing (NIPT) and offers an 
improved detection rate (DR) and fewer false positives. This test has the potential to further 
reduce the number of invasive tests performed, subsequently reducing the number of fetal 
losses due to complications (Langois & Brock, 2013). 
 
FETAL CHROMOSOMAL CONDITIONS  
Typically, individuals have 46 chromosomes or 23 pairs of chromosomes in each cell of their 
body. This is the result of proper chromosome alignment during the creation of an egg or a 
sperm. If the chromosomes do not properly align during this process, too few or too many 
chromosomes can result. This is referred to as aneuploidy and once this occurs the 
chromosome imbalance will be in every cell and cannot be treated. The cause of this 
misalignment is unknown; however, it is known that it occurs more often as women age. The 
misbalance of chromosomes can lead to development and growth challenges in the fetus, often 
resulting in spontaneous miscarriage (Prenatal Screening Ontario, 2014). The incidence of any 
fetal chromosomal condition is approximately 1 in 160 live births, with the majority of these 
being aneuploidies (Canadian Agency for Drugs and Technologies in Health, 2014). The most 
common fetal aneuploidies include Trisomy 21 (Down syndrome) and Trisomy 18 (Edward 
syndrome). Prenatal genetic screening assesses the chance of carrying a fetus with one of 
these conditions, along with assessing for open neural tube defects (ONTDs) and other 
structural chromosomal conditions. 
 
Down syndrome (Trisomy 21) 
Down syndrome is the most common aneuploidy, occurring in about 1 in 1000 births 
in Ontario (Prenatal Screening Ontario, 2014). This rate varies with age, being more 
common as women age. The common characteristic shared by those with Down 
syndrome is extra genetic material associated with chromosome 21. The effects 
associated with the extra genetic material are highly variable among individuals. 
Individuals with Down syndrome may be predisposed to certain medical and 
learning-style challenges. Common medical conditions associated with Down 
syndrome include heart, stomach, thyroid, hearing, and vision problems. Each 
individual with Down syndrome is different and there is no way to predict the level of 
disability during pregnancy. There is no cure for Down syndrome, but early 
intervention and medical management can improve the common conditions 
associated with it (Canadian Down Syndrome Society, 2009). 
 
Edward syndrome (Trisomy 18) 
Edward syndrome is less common than Down syndrome, occurring in about 1 in 
6,000 births. This condition also varies with age, being more common as women 
age. Individuals with Edward syndrome have extra genetic material associated with 
chromosome 18 and are predisposed to serious congenital malformations. Of the 
pregnancies diagnosed, 95% will result in a miscarriage and of the babies born, 
95% will die within the first year of life (Prenatal Screening Ontario, 2014).  
 
Open Neural Tube Defects (ONTDs) 
ONTDs occur when the spine or brain does not develop properly during the first 
trimester. During this time the neural tube folds together; if complete closure or 
folding of the tube does not occur, an opening remains. Depending on the location 
of this opening, the type and severity of ONTD varies. An opening lower in the spine 
is called spina bifida, which can lead to physical and intellectual disabilities. An 
opening higher in the spine is called anencephaly, which is considered incompatible 
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with life. The incidence of ONTDs in Canada is 1 in 2,000 births (Prenatal Screening 
Ontario, 2014). 
 
CURRENT SCREENING SYSTEM 
Clinical practice guidelines indicate that all pregnant women in Canada should be offered the 
option of prenatal genetic screening. This should be done through an informed counseling 
process, where non-directive information is provided and client decisions are respected 
(Chitayat, Langois, & Wilson, 2011). In Ontario, four different screening tests are available, 
three if the client presents before 14 weeks gestation and one if the client presents after 14 
weeks (Prenatal Screening Ontario, 2014). All options involve the measurement of maternal 
serum biomarkers through a maternal blood sample. This may be accompanied by a second 
maternal serum sample and/or a nuchal translucency (NT) ultrasound.1 The level of accuracy of 
each test varies, with each screen carrying a different detection rate (DR) and false positive rate 
(FPR). Screens that have a higher DR (proportion of those with the condition with a screen 
positive result) and a lower FPR (proportion of those without the condition with a screen positive 
result) are considered superior. The Society of Obstetricians and Gynecologists Canada 
(SOGC) recommends that the minimum standard of any prenatal screen for Down syndrome 
offered in Canada should be a DR of 75% and a FPR no greater than 3-5% (Chitayat et. al., 
2011). The overall accuracy of the four tests currently offered in Ontario ranges from a DR of 
75% - 90% and a FPR of 2% - 10% (Prenatal Screening Ontario, 2014; see Exhibit 1). 
 
The current available screening options that may be offered and are publically funded include: 
 
 Integrated Prenatal Genetic Screening (IPS): Has the highest DR and lowest FPR. It 
involves two maternal serum samples, one in the first trimester (before 14 weeks 
gestation) and one in the second trimester (after 14 weeks gestation). It also involves an 
NT ultrasound. Due to its superior accuracy, the majority of women in Ontario undergo 
this screen (Okun et al., 2014). 
 First Trimester Screening (FTS): This screen provides the earliest results (first 
trimester). It involves one maternal serum sample and a NT ultrasound. It has a lower 
DR and higher FPR than IPS. 
 Serum Integrated Prenatal Screening (SIPS): This test requires two maternal serum 
samples, one in the first trimester and one in the second. Few women (2%) in Ontario 
undergo this screen (Okun et al., 2014), as it does not involve NT ultrasound. This test is 
mainly used in geographical areas where first trimester ultrasound is not available 
(Chitayat et. al., 2011). 
 Maternal Serum Screen (Quad screening): This is a second trimester screen (only 
screen offered to those over 14 weeks gestation) that involves taking one maternal 
serum sample. This screen has the highest FPR. 
 
Overall, the uptake rate of screening in Ontario is estimated to be 67% (Okun et al., 2014). The 
type of screen offered and chosen may depend on geographical location, gestational age, and 
provider and client preference. In addition to one of the above screens, all pregnant women 
should be offered a detailed second trimester ultrasound (between 18 and 20 weeks gestation). 
This ultrasound screens for anatomic abnormalities, including ONTDs, and can be used to 
modify the known chance of aneuploidy established by prior screening (Chitayat et. al., 2011).  
                                               
1 NT ultrasound is done between 11 and 13 weeks gestation. It measures the thickness of tissue on the back of the 
fetus’s neck, which can be indicative of certain chromosomal conditions. Its use is recommended by the International 
Society of Prenatal Diagnosis; however, its use depends on geographical location, as some areas within the province 
do not have access to first trimester scanning expertise. 
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If a client receives a screen positive on any of these tests, it indicates that the chance of a fetal 
chromosomal condition or ONTD is higher than the specified cut-off. It does not necessarily 
mean that the fetus has one of these conditions. The majority of screen positives will be false 
positives (meaning the fetus does not actually have the condition); however, there is no way of 
knowing this until the baby is born or diagnostic testing is performed (Prenatal Screening 
Ontario, 2014). It is estimated that approximately 60% of screen positive women and 1.2% of 
screen negative women will choose to undergo diagnostic testing (Okun et al., 2014). 
 
Diagnostic Testing  
Diagnostic tests are invasive tests that are highly accurate at detecting fetal 
chromosomal conditions. Clinical practice guidelines indicate that clients who have a 
screen positive may be eligible for diagnostic testing if they are 35 years of age or 
older, have a family history of genetic chromosomal conditions, conceived through 
IVF with intracytoplasmic sperm injection, or have certain ultrasound findings 
(Prenatal Screening Ontario, 2014; Ministry of Health and Long Term Care, 2012). 
Two forms of testing exist: amniocentesis and CVS. CVS involves the removal of 
placental cells in order to analyze fetal genetic material. This procedure is 
performed between 11 and 13 weeks gestation. It carries a fetal loss risk of 1% and 
does not test for ONTDs (Prenatal Screening Ontario, 2014). The majority of women 
do not receive screening results in time for CVS and therefore their only option is 
amniocentesis (Okun et al., 2014). Amniocentesis is performed between 15 and 22 
weeks gestation and involves the removal of amniotic fluid to analyze fetal genetic 
material. This test carries a slightly lower fetal loss risk (0.01% - 0.5%, Prenatal 
Screening Ontario, 2014); however, because the procedure occurs at a later 
gestational age, women may experience increased anxiety and may be at higher 
risk of complications if choosing to terminate (Vanstone, King, deVrijier, & Nisker, 
2014). 
 
NEW DEVELOPMENTS IN PRENATAL GENETIC SCREENING 
Advances in technology have led to the development of a new type of prenatal genetic 
screening. This technology is known as non-invasive prenatal testing (NIPT) and offers the 
promise of improved accuracy and safety2 in the screening of Down syndrome. Just like current 
screening approaches, NIPT involves the analysis of a maternal blood sample. However, 
instead of analyzing maternal biomarkers (as current approaches do), NIPT analyzes fetal DNA 
found in maternal blood. This DNA is known as cell-free fetal DNA (cffDNA) and it makes up 10-
20% of the maternal plasma (Langois & Brock, 2013). With advanced technology, this DNA can 
be sequenced and analyzed for certain fetal chromosomal conditions. cffDNA can be detected 
and analyzed throughout pregnancy, starting as early as ten weeks gestation. Results are 
generally received within ten days (Vanstone et. al., 2014), opening the window to earlier 
diagnostic testing (CVS). 
 
Several clinical studies have been published assessing the use of NIPT for the detection of fetal 
chromosomal conditions. The majority of these studies have focused on the detection of Down 
syndrome among women with an increased chance of fetal chromosomal conditions. The 
results of these studies have been consistent, reporting a DR rate reaching 100% and a FPR of 
<1% (see Exhibit 2; Langois & Brock, 2013). Studies examining the effectiveness of NIPT for the 
detection of other common fetal chromosomal conditions have also been carried out, with 
similar results being reported for Trisomy 18 (see Exhibit 3; Langois & Brock, 2013). Overall, 
                                               
2 With improved accuracy, specifically a reduced false positive rate, it is expected that fewer women will undergo 
unnecessary invasive testing, which is associated with fetal loss. 
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published results suggest NIPT to be a more accurate screening approach (than the current) for 
common fetal aneuploidies in high-chance populations (Langois & Brock, 2013; Vanstone et. al., 
2014). Studies investigating the applicability of these results in average-chance populations are 
currently underway (Vanstone et. al., 2014). The largest published study to date, with a cohort 
of 2049 women, reported a DR of 100% and a FPR of <0.1% for Down syndrome and Trisomy 
18 (Nicolaides, Syngelaki, Ashoor, Birdir, & Touzet, 2012). This suggests the test may be 
universally appropriate.3 
 
As with current screening approaches, although the chance is much lower, the chance of 
receiving a false positive exists. Because of this, NIPT remains a screening tool and does not 
replace invasive testing for diagnosis. Those who would consider termination based on a 
diagnosis are still advised to undergo CVS or amniocentesis for confirmation (Langois & Brock, 
2013). In certain situations, women may have to undergo a repeat test due to initial test failure. 
This can happen in up to 6% of tests (Children’s Hospital of Eastern Ontario, 2014), often as a 
result of poor quality control measures or low fetal fraction (less than 4% cffDNA in maternal 
blood; Vanstone, et. al., 2014). Low fetal fraction may be a result of early gestation (fetal fraction 
increases as gestational age increases) or maternal obesity. Other identified limitations of the 
test include unclear results with multiple gestation pregnancies or chromosomal mosaicism.4 
 
CURRENT INTEGRATION IN ONTARIO 
In light of the evidence, the SOGC recommends NIPT be offered to women as a second tier 
screening option (Langois & Brock, 2013). This means that NIPT should be offered to 
individuals whose pregnancies have been identified as high-chance (on the basis of current 
screening modalities) and who wish to continue testing, but avoid invasive testing. Similar 
recommendations have come from other professional bodies, including the American College of 
Obstetricians and Gynecologists (American Congress of Obstetricians and Gynecologists, 
2012), the National Society of Genetic Counselors (National Society of Genetic Counselors, 
2012), and the International Society of Prenatal Diagnosis (Children’s Hospital of Eastern 
Ontario, 2014). Although NIPT is currently an available option to this population of women in 
Canada, it is expensive, costing more than $800, and for the most part is only accessible to 
those who can afford to pay for it (Okun et al., 2014). 
  
In Ontario, the MOHLTC has recently begun supporting the use of NIPT in certain 
circumstances. These circumstances are limited and are based on specific indications.5 Eligible 
providers (genetics or maternal fetal medicine specialists) who believe their client meets the 
criteria can submit an application for funding to the Ministry.6  Women who do not qualify for 
NIPT funding and who wish to have the test must find a provider who is willing to facilitate the 
process (with blood samples being sent to the U.S. for analysis) and pay out-of-pocket for the 
service. 
 
CURRENT CHALLENGES 
Jenny Black, Maternal Fetal Medicine Specialist and chair of the PGSG, has experienced 
applying to the MOHLTC on behalf of clients for funding of NIPT. Receiving variable responses 
                                               
3 The majority of studies use the gold standard of comparing the detection rate of Down syndrome by NIPT with the 
detection rate by diagnostic testing. 
4 Mosaicism is a condition in which cells within an individual have a different genetic makeup.  
5 Funding eligibility indications may include, in a singleton pregnancy, any one of the following: screen positive result, 
women > 40 years of age at expected date of delivery, NT > 3.5 mm, pregnancy history or previous child with 
aneuploidy. Other indications may include: anomalies identified on ultrasound and/or other risk factors (MOHLTC, 
2014). 
6 Approval from the ministry must be received prior to receiving the services (MOHLTC, 2014). 
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from the MOHLTC and having few applications approved, Jenny has not been satisfied with the 
current process. Discussing her challenges with colleagues, Jenny heard her frustrations being 
echoed. Following the annual Ontario conference on new developments in prenatal genetics, 
Jenny met with providers (midwives, family physicians, and genetic counselors) from across the 
province to discuss their experience with NIPT. From the meeting, Jenny realized that confusion 
regarding the appropriate use and funding of NIPT in Ontario was strong. Inconsistencies in 
practice were common, with some providers offering the test to all clients (mainly out of liability 
concern), while others were just learning of the new technology and had not been offering it at 
all. 
 
Jenny suspected that much of the confusion and variability in practice was attributable to the 
rapid emergence of this new technology through the private market. Wanting to support the 
ministry’s vision of a centralized, standardized, high quality screening program for Ontario 
(Okun et al., 2014), Jenny knew changes to the current system would need to be made. She 
also knew that the changes would need to be cost-effective, as resources were scarce within 
the publicly funded system. 
 
ECONOMIC EVALUATION7 OF NIPT INTEGRATION OPTIONS (OKUN et. al., 2014) 
Different scenarios have been proposed for which the Ministry could introduce NIPT into the 
public system. This includes NIPT as a second-tier contingency screen or NIPT as the primary 
screen. These scenarios are compared to the current system, where NIPT remains mainly 
within the private market. Three algorithms (see Exhibit 4) are presented, demonstrating the 
screening pathway of each scenario. Numbers informing the algorithms and evaluation were 
retrieved from the provincial Better Outcomes Registry Network (BORN) (fiscal year 2012-2013) 
and the five Ontario regional laboratories. This includes data on test performance and cost, 
number of total pregnancies, expected number of cases of Down syndrome, uptake of 
screening and diagnostic testing, and pregnancy loss rate due to diagnostic testing (see 
Exhibit 5). 
 
Within each scenario the system performance and costs are analyzed (see Exhibit 6). The 
performance outcomes analyzed include the total number of cases of Down syndrome detected, 
the total number of invasive tests (amniocentesis) performed, and the total number of fetal 
losses (false positive cases) related to invasive testing. The cost outcomes include the total cost 
of the screening program (up to and including prenatal diagnosis of Down syndrome), the cost 
per woman screened, and the cost per case of Down syndrome detected. 
 
Overall assumptions within the evaluation include: 
 Diagnostic testing may be directly offered to women identified as high-chance for fetal 
chromosomal conditions; 
 Diagnostic testing following primary screening is amniocentesis whereas NIPT is 
accompanied with a first trimester ultrasound; 
 Where contingent NIPT screening follows FTS as the primary screen8 it is assumed that 
100% of those who receive a screen positive after FTS will undergo NIPT and 100% of 
those who receive a positive result after NIPT will undergo amniocentesis; and  
                                               
7 Information informing this section was retrieved from the economic evaluation conducted by Okun et. al., (2014). 
This is a recent 2014 Ontario study, with its quality being validated within a critical appraisal by the Canadian Agency 
for Drugs and Technologies in Health. 
8 FTS is the only screening option that provides results within the first trimester. Using this screen as the primary 
screen ensures NIPT (if warranted) can be performed within a reasonable time. FTS has a DR of up to 85% and FPR 
of up to 9%. The high FPR is not of concern as screen positives will be screened with NIPT prior to diagnostic testing. 
The lower DR however means that fewer cases of Down syndrome may be detected than if IPS were used. 
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 A provincial lead centre will be established to monitor and evaluate NIPT and therefore 
an operating cost of $1,044,000 is added to the scenarios that include publicly funded 
NIPT. 
 
1. NIPT as a Commercial Test  
NIPT would remain in the private market, with companies promoting its use directly to the 
public and providers. Two different models were used to demonstrate this scenario (models 
1-2 in Exhibit 6), with one using current FTS/IPS screening modalities and one using FTS as 
the only screening modality. Based on the evaluation of these models, the total screening 
costs to the system would range from $17,353,789-$17,580,080, with the cost per woman 
screened being $179-$182, and the cost per case of Down syndrome diagnosed being 
$112,919-$114,391. The performance of this scenario includes 3,211-4,247 invasive 
procedures being performed, 154 cases of Down syndrome being detected, and 31-41 
procedure-related fetal losses occurring. 
 
2. NIPT as a Contingency Test (second-tier screening) 
The use of NIPT as a contingent test would mean it is only offered to individuals based on 
certain criteria. In this evaluation, NIPT is only offered to women who receive a screen 
positive following FTS. Five different contingent NIPT models were created (models 4-8 in 
Exhibit 6). These models depict possible alternatives and are based on the assumption that 
as technology becomes safer and more accurate the rate of uptake will be higher, the 
accuracy of FTS will improve with continued research and quality assurance, and the cost of 
NIPT will decrease over time. Taking the different models into consideration, it is estimated 
that the total cost of screening to the system will range from $17,353,081 to $21,372,742, 
with the cost per woman screened being $179-$208, and the cost per case of Down 
syndrome diagnosed being $68,530-$71,474. The performance of this scenario includes 
293-1,358 invasive procedures being performed, 253-337 cases of Down syndrome being 
detected, and 0-13 procedure-related fetal losses occurring. 
 
3. NIPT as the Primary Testing Method  
In this scenario (model 3 in Exhibit 6), NIPT would replace the current primary screening 
options and would be offered to all pregnant women. This scenario is estimated to cost the 
system a total of $85,146,250 with the cost per woman screened being $879, and the cost 
per case of Down syndrome diagnosed being $286,428. The performance of this scenario 
includes 394 invasive procedures being performed, 297 cases of Down syndrome being 
detected, and 1 procedure-related fetal loss occurring. 
 
RECOMMENDATION 
Based on the evaluation, the introduction of NIPT into the public system would result in more 
cases of Down syndrome being detected, fewer invasive tests being performed, and fewer 
related pregnancy losses. However these benefits would come with an increased cost to the 
healthcare system. NIPT as a primary test (which evidence does not yet fully support, but may 
relatively soon) significantly increases the cost to the system, costing four to five times more 
than the current system. NIPT as a contingency test is a more feasible option, costing slightly 
more than the current system, yet deriving similar benefits to that of the primary approach. 
 
Taking the economic evaluation into consideration, along with other relevant decision-making 
elements, Jenny, together with the PGSG, needs to make recommendations to the MOHLTC for 
an improved prenatal genetic screening program in Ontario. 
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EXHIBIT 1 
Current Prenatal Genetic Screening Options in Ontario 
 
Tests 
Down 
syndrome 
DR 
Down 
syndrome 
FPR 
Comments 
Integrated Prenatal 
Screening (IPS) 
First Trimester (11-13+6/7 
wks) 
- NT – by registered 
sonographer 
- maternal serum: 
PAPP-A 
Second Trimester (15-
20+6/7 wks) 
- maternal serum: AFP, 
hCG, uE3 
85-90% 2-4% 
- Results available in 2nd trimester after blood 
taken 
 
- Diagnostic test after counselling for screen 
positive = amniocentesis 
Serum Integrated 
Prenatal Screening 
(SIPS) 
First Trimester (11-13+6/7 
wks) 
- maternal serum: 
PAPP-A 
Second Trimester (15-
20+6/7 wks) 
- maternal serum: AFP, 
hCG, uE3, DIA 
80-90% 2-7% 
- Results available in 2nd trimester after blood 
taken 
 
- Diagnostic test after counselling for screen 
positive = amniocentesis 
 
- Is available in most places where NT ultrasound 
is not available 
(*) First Trimester 
Combined Screening 
(FTS) 
First Trimester (11-13+6/7 
wks) 
- NT – by registered 
sonographer 
- maternal serum: 
PAPP-A, ƒbhCG 
78-85% 3-9% 
- Results available in 1st trimester after blood 
taken – usually end of 1st trimester, earliest results 
 
- CVS for diagnostic testing 
 
- Does not screen for NTD* 
(*) First trimester screening is not available in all areas of Ontario 
* NTDs (open neural tube defects) can be screened for by MS-AFP and/or ultrasound at 18-20 weeks 
DR: detection rate – also known as sensitivity, is the probability that a fetus affected with Down syndrome will be 
detected by the prenatal test 
FPR: false positive rate – the proportion of women with unaffected pregnancies who have positive results 
: increased value 
: decreased value 
 
Test 
Down 
syndrome DR 
Down syndrome 
FPR Comments 
Maternal Serum Screen (Quadruple 
Screening – MSS) 
Second Trimester (15-20+6/7 wks) 
- maternal serum: AFP, hCG, uE3, 
DIA 
 
75-85% 
 
5-10% 
- Results available in 2nd 
trimester  
- Amniocentesis for 
diagnostic testing 
 
Source: Prenatal Screening Ontario, 2014b. 
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EXHIBIT 2 
Published Studies Examining the Use of NIPT for the Detection of Down Syndrome 
 
Table 2. Results of validation studies for non-invasive detection of fetal trisomy 21 
Study 
Number 
samples tested Failure rate* 
Sequencing 
approach 
Detection 
rate 
False- 
positive rate 
Chiu et al. 20118 764 
232 
1.4% 
N/A 
8-plex shotgun 
2-plex shotgun 
79.1% (68/86) 
100% (86/86) 
1.1% 
2.1% 
Palomaki et al. 
20119 
1696 0.8% 4-plex shotgun 98.6% (209/212) 
95% Cl 95.9 to 99.7 
0.2% 
95% Cl <0.1 to 0.6 
Ehrich et al. 201110 467 3.9% 4-plex shotgun 100% (39/39) 
95% Cl 89 to 100 
0.2% 
95% Cl 0.1 to 1.5 
Lau et al. 201111 108 0 12-plex shotgun 100% (11/11) 0 
Sehnert et al. 201212 47 0 1-plex shotgun 100% (13/13) 0 
Sparks et al. 201213 167 0† 96-plex selective 100% (36/36) 0.8% 
Ashoor et al. 201214 400 0.75% 96-plex selective 100% (50/50) 0 
Bianchi et al. 201215 532 3% 6-plex 100% (89/89) 
95% Cl 95.9 to 100 
0 
Norton et al. 201216 3228 4.5% 96-plex selective 100% (81/81) 
95% Cl 95.5 to 100 
0.03% 
35% Cl 0.002 to 0.2 
*Percentage of samples that did not meet quality control requirements for the sequencing so that no results could be obtained. 
 
†5% failure in their training set. 
 
N/A: not applicable – only samples that passed original sequencing quality control were retested within the 2-plex. 
 
Source: Langois & Brock, 2013 (by permission of The Society of Obstetricians and Gynaecologists of Canada). 
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EXHIBIT 3 
Published Studies Examining the Use of NIPT for the Detection of Trisomy 18 
 
Table 3. Results of validation studies for non-invasive detection of fetal trisomy  
Study Sequencing 
approach 
Trisomy 18 
detection rate 
Trisomy 18  
false-positive rate 
Lau et al. 201111 12-plex shotgun 90% (9/10) 0 
Sehnert et al. 201212 1-plex shotgun 100% (8/8) 0 
Sparks et al. 201213 96-plex selective 100% (8/8) 0.8% 
Ashoor et al. 201214 96-plex selective 98% (49/50) 0 
Bianchi et al. 201215 6-plex 97.2% (35/36) 0 
Norton et al. 201215 96-plex selective 97.4% (37/38) 0.07% 
Palomaki et al. 201215 4-plex shotgun 100% (59/59) 0.28% 
 
Source: Langois & Brock, 2013 (by permission of The Society of Obstetricians and Gynaecologists of Canada).  
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Pregnancies in 
Ontario 
No Screening 
Screening 
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Algorithms of Screening Pathways 
 
 
 
1. Current model  
 
 
 
 
 
 
 
 
 
 
2. Contingent model  
 
 
 
 
 
 
 
 
 
 
3. Primary model  
 
 
 
 
 
 
 
 
Source: Adapted from Okun et. al., 2014. 
Deciding Value for Money: Improving Prenatal Genetic Screening in Ontario 
22 
 
EXHIBIT 5 
Evaluation Assumptions 
 
Table 1 Background conditions and assumptions for various scenarios of prenatal screening for Down 
syndrome in Ontario 
 
    
Contingent cffDNA 
Conditions/ 
assumptions 
Current 
system, No 
cffDNA (1) 
FTS, 
No 
cffDNA  
(2) 
Primary 
cffDNA DS 
screen (3) 
Current FTS 
performance 
(4) 
Cost 
recovery 
(5) 
Improved 
DR (6) 
Higher 
uptake (7) 
Optimized 
FTS (8) 
# total pregnancies 144 570 144 570 144 570 144 570 144 570 144 570 144 570 144 570 
Expected number of cases 
of DS 
448 448 448 448 448 448 448 448 
Uptake of prenatal 
screening 
67% 67% 67% 67% 67% 67% 80% 80% 
Number of screened 
pregnancies 
96 862 96 862 96 862 96 862 96 862 96 862 115 656 115 656 
Detection rate of IPS/FTS 85% 85% 99% 85% 85% 95% 85% 95% 
Positive rate 3.6% 5.4% 0.1% 5.4% 5.4% 11.2% 5.4% 11.2% 
Rate of diagnostic testing 
among screen-positive 
women 
60% 60% 100% 100% 100% 100% 100% 100% 
Rate of diagnostic testing 
among screen-negative or 
no screening group 
1.2% 1.2% 0% 1.2% 1.2% 0% 1.2% 0% 
Pregnancy loss rate due to 
amniocentesis (ref RCT) 
1% 1% 1% 1% 1% 1% 1% 1% 
Cost of  cffDNA test (ref) __ __ $795 $795 $744 $795 $795 $600 
cffDNA, cell-free fetal DNA; FTS, first trimester screening; DS, Down syndrome; DR, detection rate; IPS, integrated prenatal screening. 
 
Source: Okun et. al., 2014 (by permission of John Wiley and Sons and Copyright Clearance Center). 
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EXHIBIT 6 
Evaluation Outcomes: Models 1-3 
 
Table 2 Performance and cost outcomes with different modeled 
scenarios of prenatal screening for Down syndrome in Ontario 
 
Outcomes 
Current 
system, No 
cffDNA (1) 
FTS, No 
cffDNA (2) 
Primary 
cffDNA DS 
screen (3)a 
# amniocentesis 
performed 
3211b 4247b 394c 
# prenatal cases of DS 
detected prenatally 
154 154 297 
# amniocenteses related 
losses of non-DS 
affected pregnancies 
31 41 1 
Total program cost $17 353 789 $17 580 080 $85 146 250 
Cost/woman screened $179 $182 $879 
Cost/prenatally 
diagnosed pregnancy 
with DS 
$112 919 $114 391 $286 428 
Cost/additional 
prenatally diagnosed 
pregnancy with DS 
__ __ $472 139 
cffDNA, cell-free DNA; FTS, first trimester screening; DS, Down syndrome. 
aIncludes cost of first trimester ultrasound. 
bAssumes 1.2% of screen-negative women continue to request amniocentesis. 
cAssumes only contingent screen-positive women undergo amniocentesis 
 
Source: Okun et. al., 2014 (by permission of John Wiley and Sons and Copyright Clearance Center). 
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EXHIBIT 7 
Evaluation Outcomes: Models 4-8 
 
Table 3 Performance and cost outcomes with different cell-free fetal DNA contingent modeled scenarios  
Outcomes  
Contingent cffDNA with 
current FTS performance 
(4) 
Contingent cffDNA 
with Cost recovery 
(5) 
Contingent cffDNA 
with Improved DR 
(6) 
Contingent cffDNA 
with Higher uptake 
(7) 
Contingent cffDNA 
with Optimized FTS 
(8) 
# amniocentesis performed 1358a 1358a 293b 1621a 350b 
# prenatal cases of DS 
detected prenatally 
253 253 282 302 337 
# amniocenteses related 
losses of non-DS affected 
pregnancies 
11 11 0 13 0 
Total program cost $17 619 839 $17 353 081 $20 184 795 $20 836 046 $21 372 742 
Cost/woman screened $182 $179 $208 $180 $185 
Cost/prenatally diagnosed 
pregnancy with DS 
$69 583 $68 530 $71 474 $68 913 $63 383 
Cost/additional prenatally 
diagnosed pregnancy with 
DS 
$2673 $0 $21 933  $23 423 $21 900 
cffDNA, cell-free DNA; FTS, first trimester screening; DS, Down syndrome. 
aAssumes 1.2% of screen-negative women continue to request amniocentesis. 
bAssumes only contingent screen-positive women undergo amniocentesis. 
 
Source: Okun et. al., 2014 (by permission of John Wiley and Sons and Copyright Clearance Center). 
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BACKGROUND 
Since 1993, the Ontario Ministry of Health and Long-Term Care (MOHLTC) has financed 
prenatal genetic screening through its provincial health insurance plan. In 2013, a new 
technology became available. Non-invasive prenatal testing (NIPT) promises improved 
accuracy and screening safety at a higher cost than other screening tests. Since 2013, pregnant 
women in Ontario have been paying for the test themselves. In March 2014, the Ministry 
appointed a Prenatal Genetic Screening Group (PGSG), to make recommendations on making 
NIPT available through the provincial health insurance plan. The Ministry requested an 
economic evaluation, appraising the value of NIPT. 
 
OBJECTIVES 
1. Understand the role of economic evaluation in health policy decision-making 
2. Critically appraise the quality of an economic evaluation and evaluate its applicability 
3. Interpret economic evaluations and use the results to inform policy recommendations 
4. Discuss the challenges of interpreting cost-effectiveness analysis as compared to cost-utility 
analysis 
5. Consider broader social, political, and ethical concerns such as equity, quality assurance, 
allocative efficiency, and appropriate use of screening in making health policy decisions 
 
DISCUSSION QUESTIONS 
1. How should scarce resources be allocated within a publically funded healthcare system? 
2. What type of economic evaluation was performed (cost-minimization, cost-effectiveness, 
cost-utility, cost-benefit)? 
3. How would you appraise the quality of the economic evaluation? Is it adequate for use in 
policy decision-making? 
4. What are the challenges associated with using the cost per case of Down syndrome 
diagnosed as a measure of value for money? Are there additional analyses you would 
recommend? 
5. What recommendations would you make about NIPT screening based on the results of 
economic evaluation?  
6. Are there important factors not addressed by the economic evaluation? 
7. Should the ministry allocate resources to supporting parents of children with Down 
syndrome? 
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